Skip to main content

Table 2 Results from meta-analyses conducted independently by Centers A and B examining measures of efficacy and safety associated with rhBMP-2

From: Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic Project

Outcome Center Surgical approach No. of studies (n) Effect size (95% CI) Treatment advantage
ODI A All 12 (1368) (0-100) -3.48 (-6.47 to -0.49) BMP
B ALIF 5 (423) (0-50) -7.35 (-14.00 to -0.70) BMP
PLF 4 (650) (0-50) -1.98 (-4.86 to 0.90) Neither
SF-36 PCS A All 12 (1303) (0-100) 1.93 (0.63 to 3.22) BMP
B ALIF 5 (421) (0-100) 3.68 (0.86 to 6.49) BMP
PLF 4 (644) (0-100) 1.10 (-0.6 to 2.86) Neither
Back pain A All 12 (1326) (0-10) -1.58 (-2.65 to -0.51) BMP
B ALIF 4 (409) (0-20) -0.74 (1.49 to 0.00) BMP
PLF 4 (649) (0-20) -0.31 (-0.76 to 0.15) Neither
Leg pain A All 12 (1326) (0-10) -0.59 (-1.27 to 0.09) Neither
B ALIF 4 (409) (0-20) -0.60 (-1.28 to 0.08) Neither
PLF 4 (648) (0-20) -0.34 (-0.82 to 0.13) Neither
Fusion A All 10 (1078) RR 1.14 (1.03 to 1.25) BMP
B ALIF 5 (416) RR 1.05 (0.88 to 1.24) Neither
PLF 4 (637) RR 1.16 (0.96 to 1.41) Neither
Cancer A All up to 48 months 11 (1281) RR 1.98 (0.86 to 4.54) Neither
B All 24 months 5 (1450) RR 3.45 (1.98 to 6.00) Control
All 48 months 4 (1183) RR 1.82 (0.84 to 3.95) Neither
  1. CI Confidence Interval, ODI Oswestry disability index. Lower favors rhBMP-2. ALIF Anterior lumbar interbody fusion, PLF Posterolateral fusion, RR Relative risk, SF-36 PCS Short Form 36 Physical Component Score. Higher favors rhBMP-2. For back and leg pain, Center A used a 0-10 scale and Center B used a 0-20 scale. Lower favors rhBMP-2. Bolded values statistically significant